The report titled ‘Global ADC Contract Manufacturing Market: Industry Trends and Forecasts, 2024 to 2035’ has been released on ResearchAndMarkets.com. It provides comprehensive insights into the ADC contract manufacturing sector, estimating its value at $1.79 billion in 2024 and projecting a CAGR of 13% to reach approximately $6.87 billion by 2035.
Key aspects covered include industry trends, market analysis, service provider landscape, competitiveness, expansions, partnerships, capacity analysis, clinical trials, demand analysis, value chain assessment, market impact, and opportunity analysis. The increasing demand for antibody drug conjugates (ADCs) underscores market growth, driven by their efficacy in targeting various cancers with enhanced specificity and reduced side effects.
The report highlights the complexities of ADC manufacturing, such as technological challenges and cost-intensive processes, leading pharmaceutical developers to outsource to ADC contract manufacturers (CMOs). These CMOs are expanding their capabilities to offer comprehensive services, aiming to meet rising industry demands effectively.
Geographically, North America hosts a significant portion of the ADC contract manufacturing companies, with notable concentrations in Europe, particularly Switzerland. Key players in this market include Lonza, MilliporeSigma, Catalent Pharma Solutions, and WuXi Biologics, among others, actively contributing to market dynamics and growth.
For more detailed insights, the report features a 510-page analysis covering market dynamics, company profiles, and an Excel database for comprehensive information retrieval. More details can be found on ResearchAndMarkets.com under the report link: [link].
